Copper-67 from Iotron Medical
Copper-67 fromIotron Medical

Clinical trials experience

Despite the challenges traditionally associated with copper-67 production a number of highly successful human clinical trials have been performed with antibodies linked to copper-67 payload, demonstrating high response rates, higher tumor uptake and doses, and longer residence time in tumor than alternate radioisotopes. The targeted diseases include Non-Hodgkin Lymphoma (NHL), colon and bladder cancer.


New clinical trials are now underway.

Click on the links below to access published articles, or contact us for further information:

Iotron Medical, a spin-out business of Iotron Industries - providing innovative solutions using electron beam technology for more than 25 years



Contact us today!

If you have any queries or wish to contact us:


For partnering opportunities:


To buy radioisotope:



Print Print | Sitemap
© Iotron Medical Inc 2021